Research map
78 papers · threads of research
ETS2 / Functional Genomics
A new master switch on chromosome 21 that turns immune cells inflammatory across AS, IBD, and other related conditions.
HLA-B27 Genetics
The gene most strongly linked to AS, and what flips it from a risk factor into active disease.
Gut–Immune Axis
How gut bacteria, the gut barrier, and the immune cells lining the gut all influence inflammation in AS.
Macrophage M1 Polarisation
The immune cells stuck in inflammatory mode. Where most AS treatments aim, indirectly.
IL-23 / IL-17 Axis
The cytokine pathway most newer AS biologics target, secukinumab, ixekizumab, bimekizumab.
TNF-α Inhibition
The first major shift in AS treatment. Still first-line in most guidelines.
JAK–STAT Pathway
The newer oral pill option, tofacitinib, upadacitinib, filgotinib.
Cell Therapy (CAR-T / MSC)
The frontier, mostly preclinical for AS, but moving fast in adjacent autoimmune conditions.
Treatment Response & Outcomes
What actually happens to people on treatment: remission, tapering, switching, long-term damage, and the questions patients ask.
Threads with red string between them share mechanism, gut inflammation drives Th17 cells, which drive IL-17, which is what most newer drugs target.
Editor's note · 03/05
When a paper is approved, it pins to its thread. The first ones land via the contribute form below.
Pinned 03/05
See something missing?
Patients catch papers researchers miss. Researchers catch papers patients can’t access. If you’ve found a paper, preprint, or resource that belongs on the board, suggest it →
View threads as a list
ETS2 / Functional Genomics
A new master switch on chromosome 21 that turns immune cells inflammatory across AS, IBD, and other related conditions.
HLA-B27 Genetics
The gene most strongly linked to AS, and what flips it from a risk factor into active disease.
Gut–Immune Axis
How gut bacteria, the gut barrier, and the immune cells lining the gut all influence inflammation in AS.
Macrophage M1 Polarisation
The immune cells stuck in inflammatory mode. Where most AS treatments aim, indirectly.
IL-23 / IL-17 Axis
The cytokine pathway most newer AS biologics target, secukinumab, ixekizumab, bimekizumab.
TNF-α Inhibition
The first major shift in AS treatment. Still first-line in most guidelines.
JAK–STAT Pathway
The newer oral pill option, tofacitinib, upadacitinib, filgotinib.
Cell Therapy (CAR-T / MSC)
The frontier, mostly preclinical for AS, but moving fast in adjacent autoimmune conditions.
Treatment Response & Outcomes
What actually happens to people on treatment: remission, tapering, switching, long-term damage, and the questions patients ask.